GIPR and Obesity: When administered peripherally, particularly antibody-based GIPR antagonists demonstrate some potential to prevent the development of HFD-induced obesity in rodents (181, 186), but GIPR antagonists show only modest, if any ability to decrease body weight once obesity is already established (181, 183–186).